Symbols / HROW $36.26 +0.50%
HROW Chart
About
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 1.35B |
| Enterprise Value | 1.52B | Income | -5.14M | Sales | 272.30M |
| Book/sh | 1.41 | Cash/sh | 2.02 | Dividend Yield | — |
| Payout | 0.00% | Employees | 373 | IPO | — |
| P/E | — | Forward P/E | 15.56 | PEG | — |
| P/S | 4.96 | P/B | 25.73 | P/C | — |
| EV/EBITDA | 31.13 | EV/Sales | 5.58 | Quick Ratio | 1.93 |
| Current Ratio | 2.20 | Debt/Eq | 483.72 | LT Debt/Eq | — |
| EPS (ttm) | -0.14 | EPS next Y | 2.33 | EPS Growth | -10.30% |
| Revenue Growth | 33.30% | Earnings | 2026-05-07 | ROA | 4.84% |
| ROE | -8.47% | ROIC | — | Gross Margin | 75.05% |
| Oper. Margin | 17.50% | Profit Margin | -1.89% | Shs Outstand | 37.23M |
| Shs Float | 27.34M | Short Float | 19.50% | Short Ratio | 11.45 |
| Short Interest | — | 52W High | 54.85 | 52W Low | 20.85 |
| Beta | 0.10 | Avg Volume | 710.93K | Volume | 470.36K |
| Target Price | $69.62 | Recom | Strong_buy | Prev Close | $36.08 |
| Price | $36.26 | Change | 0.50% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$69.63
Mean price target
2. Current target
$36.26
Latest analyst target
3. DCF / Fair value
$21.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$36.26
Low
$59.00
High
$91.00
Mean
$69.63
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-04 | main | Cantor Fitzgerald | Overweight → Overweight | $91 |
| 2026-03-04 | main | HC Wainwright & Co. | Buy → Buy | $70 |
| 2025-11-12 | main | Ladenburg Thalmann | Buy → Buy | $66 |
| 2025-11-12 | main | HC Wainwright & Co. | Buy → Buy | $69 |
| 2025-10-01 | reit | B. Riley Securities | Buy → Buy | $74 |
| 2025-09-29 | main | Lake Street | Buy → Buy | $70 |
| 2025-09-29 | reit | HC Wainwright & Co. | Buy → Buy | $64 |
| 2025-09-29 | reit | BTIG | Buy → Buy | $63 |
| 2025-09-24 | reit | BTIG | Buy → Buy | $63 |
| 2025-09-23 | main | B. Riley Securities | Buy → Buy | $70 |
| 2025-09-23 | main | Craig-Hallum | Buy → Buy | $64 |
| 2025-09-23 | reit | BTIG | Buy → Buy | $63 |
| 2025-08-14 | main | BTIG | Buy → Buy | $63 |
| 2025-08-13 | main | HC Wainwright & Co. | Buy → Buy | $64 |
| 2025-07-11 | init | Cantor Fitzgerald | — → Overweight | $76 |
| 2025-06-10 | init | William Blair | — → Outperform | — |
| 2025-05-12 | main | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-04-01 | main | B. Riley Securities | Buy → Buy | $65 |
| 2025-03-31 | reit | HC Wainwright & Co. | Buy → Buy | $57 |
| 2025-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $57 |
- Buy or Sell Harrow Stock? - Trefis Fri, 06 Mar 2026 07
- Harrow Shares Collapse, Another Opportunity? (NASDAQ:HROW) - Seeking Alpha ue, 03 Mar 2026 19
- $HROW stock is down 18% today. Here's what we see in our data. - Quiver Quantitative ue, 03 Mar 2026 14
- Has The Recent Slide In Harrow (HROW) Opened A Valuation Opportunity For Investors - simplywall.st Fri, 06 Mar 2026 16
- A Look At Harrow (HROW) Valuation After Mixed Q4 Results And 2026 Profitability Concerns - Yahoo Finance Fri, 06 Mar 2026 03
- Harrow (NASDAQ:HROW) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat Wed, 04 Mar 2026 13
- Eye drug TRIESENCE moves into Phase 3 test to ease cataract surgery recovery - Stock Titan ue, 03 Mar 2026 08
- Harrow Health Updates Investor Presentation via Regulation FD Filing - TipRanks ue, 10 Mar 2026 12
- HROW: Record growth and expanding ophthalmic portfolio drive optimism for future launches - TradingView ue, 10 Mar 2026 13
- Harrow, Inc. (HROW): A Bull Case Theory - Finviz Sat, 28 Feb 2026 08
- Analysts Boost Profit Forecasts On Two Names. One Is A Data Center Play. - Investor's Business Daily ue, 24 Feb 2026 13
- Would You Still Hold Harrow Stock If It Fell Another 30%? - Trefis Wed, 04 Mar 2026 06
- A Look At Harrow (HROW) Valuation After Q4 2025 Earnings Miss And Raised 2026 Spending Plans - simplywall.st hu, 05 Mar 2026 14
- Harrow (HROW) Misses Q4 Earnings Estimates - Yahoo Finance Mon, 02 Mar 2026 23
- Harrow, Inc. $HROW Shares Sold by Royce & Associates LP - MarketBeat Mon, 02 Mar 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 198572 | 7846426.0 | — | Sale at price 39.15 - 39.67 per share. | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2026-03-04 00:00:00 | I |
| 1 | 5000 | 270900.0 | — | Sale at price 54.18 per share. | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-27 00:00:00 | I |
| 2 | 20000 | 1066914.0 | — | Sale at price 53.35 per share. | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2026-01-06 00:00:00 | I |
| 3 | 180000 | 711000.0 | — | Conversion of Exercise of derivative security at price 3.95 per share. | BAUM MARK L | Chief Executive Officer | — | 2025-12-12 00:00:00 | D |
| 4 | 60000 | 237000.0 | — | Conversion of Exercise of derivative security at price 3.95 per share. | BOLL ANDREW R | President | — | 2025-12-12 00:00:00 | D |
| 5 | 600000 | 4722000.0 | — | Conversion of Exercise of derivative security at price 7.87 per share. | BAUM MARK L | Chief Executive Officer | — | 2025-07-21 00:00:00 | D |
| 6 | 30204 | 923827.0 | — | Sale at price 30.37 - 30.80 per share. | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-10 00:00:00 | I |
| 7 | 4796 | 144024.0 | — | Sale at price 30.02 - 30.04 per share. | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-04 00:00:00 | I |
| 8 | 15000 | 391904.0 | — | Sale at price 25.90 - 26.59 per share. | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-13 00:00:00 | I |
| 9 | 762300 | nan | — | — | BAUM MARK L | Chief Executive Officer | — | 2025-04-03 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.63M | -719.04K | -578.13K | 492.45K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | 50.24M | 23.43M | 12.71M | -5.45M |
| TotalUnusualItems | -7.75M | -3.42M | -2.75M | 2.35M |
| TotalUnusualItemsExcludingGoodwill | -7.75M | -3.42M | -2.75M | 2.35M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -5.14M | -17.48M | -24.41M | -14.09M |
| ReconciledDepreciation | 19.68M | 14.54M | 12.34M | 3.67M |
| ReconciledCostOfRevenue | 67.93M | 49.24M | 39.64M | 25.38M |
| EBITDA | 42.49M | 20.00M | 9.95M | -3.10M |
| EBIT | 22.81M | 5.47M | -2.39M | -6.77M |
| NetInterestIncome | -24.18M | -22.79M | -21.32M | -7.24M |
| InterestExpense | 24.18M | 22.79M | 21.32M | 7.24M |
| NormalizedIncome | 983.50K | -14.78M | -22.24M | -15.94M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -5.14M | -17.48M | -24.41M | -14.09M |
| TotalExpenses | 241.79M | 190.54M | 129.38M | 86.68M |
| TotalOperatingIncomeAsReported | 30.52M | 8.82M | 431.00K | 1.92M |
| DilutedAverageShares | 36.76M | 35.65M | 32.62M | 27.62M |
| BasicAverageShares | 36.76M | 35.65M | 32.62M | 27.62M |
| DilutedEPS | -0.14 | -0.49 | -0.75 | -0.51 |
| BasicEPS | -0.14 | -0.49 | -0.75 | -0.51 |
| DilutedNIAvailtoComStockholders | -5.14M | -17.48M | -24.41M | -14.09M |
| NetIncomeCommonStockholders | -5.14M | -17.48M | -24.41M | -14.09M |
| PreferredStockDividends | 472.00K | |||
| NetIncome | -5.14M | -17.48M | -24.41M | -14.09M |
| MinorityInterests | 0.00 | |||
| NetIncomeIncludingNoncontrollingInterests | -5.14M | -17.48M | -24.41M | -14.09M |
| NetIncomeContinuousOperations | -5.14M | -17.48M | -24.41M | -14.09M |
| TaxProvision | 3.77M | 161.00K | 701.00K | 75.00K |
| PretaxIncome | -1.37M | -17.32M | -23.71M | -14.01M |
| OtherIncomeExpense | -7.70M | -3.61M | -3.20M | -8.69M |
| OtherNonOperatingIncomeExpenses | 47.00K | -185.00K | -444.00K | 102.00K |
| SpecialIncomeCharges | -7.75M | -253.00K | -5.84M | 5.26M |
| GainOnSaleOfPPE | 0.00 | 5.26M | 0.00 | |
| OtherSpecialCharges | 7.75M | 5.46M | -1.21M | |
| ImpairmentOfCapitalAssets | 0.00 | 253.00K | 380.00K | 0.00 |
| EarningsFromEquityInterest | 0.00 | -11.13M | -5.33M | |
| GainOnSaleOfSecurity | -3.17M | 3.09M | -2.91M | -10.13M |
| NetNonOperatingInterestIncomeExpense | -24.18M | -22.79M | -21.32M | -7.24M |
| TotalOtherFinanceCost | 7.24M | 5.44M | ||
| InterestExpenseNonOperating | 24.18M | 22.79M | 21.32M | 7.24M |
| OperatingIncome | 30.52M | 9.07M | 811.00K | 1.92M |
| OperatingExpense | 173.85M | 141.29M | 89.74M | 61.29M |
| ResearchAndDevelopment | 20.94M | 12.23M | 6.65M | 3.05M |
| SellingGeneralAndAdministration | 152.91M | 129.06M | 83.09M | 58.24M |
| GrossProfit | 204.37M | 150.37M | 90.55M | 63.21M |
| CostOfRevenue | 67.93M | 49.24M | 39.64M | 25.38M |
| TotalRevenue | 272.30M | 199.61M | 130.19M | 88.59M |
| OperatingRevenue | 271.91M | 198.62M | 117.45M | 88.59M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 37.23M | 35.62M | 35.17M | 29.90M |
| ShareIssued | 37.23M | 35.62M | 35.17M | 29.90M |
| NetDebt | 170.26M | 172.29M | 111.80M | 7.90M |
| TotalDebt | 251.98M | 228.83M | 193.22M | 112.23M |
| TangibleBookValue | -124.24M | -117.38M | -91.61M | 1.43M |
| InvestedCapital | 295.63M | 289.19M | 256.65M | 131.77M |
| WorkingCapital | 115.45M | 98.31M | 90.14M | 99.63M |
| NetTangibleAssets | -124.24M | -117.38M | -91.61M | 1.43M |
| CapitalLeaseObligations | 8.79M | 9.29M | 7.33M | 8.05M |
| CommonStockEquity | 52.45M | 69.65M | 70.77M | 27.59M |
| TotalCapitalization | 295.63M | 289.19M | 256.65M | 131.77M |
| TotalEquityGrossMinorityInterest | 52.09M | 69.30M | 70.41M | 27.24M |
| MinorityInterest | -355.00K | -355.00K | -355.00K | -355.00K |
| StockholdersEquity | 52.45M | 69.65M | 70.77M | 27.59M |
| RetainedEarnings | -156.52M | -151.38M | -133.90M | -109.49M |
| AdditionalPaidInCapital | 208.93M | 221.00M | 204.63M | 137.06M |
| CapitalStock | 37.00K | 35.00K | 35.00K | 30.00K |
| CommonStock | 37.00K | 35.00K | 35.00K | 30.00K |
| TotalLiabilitiesNetMinorityInterest | 347.39M | 319.67M | 241.75M | 130.14M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 251.09M | 228.33M | 192.41M | 111.51M |
| NonCurrentAccruedExpenses | 2.71M | 0.00 | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 251.09M | 228.33M | 192.41M | 111.51M |
| LongTermCapitalLeaseObligation | 7.91M | 8.79M | 6.52M | 7.33M |
| LongTermDebt | 243.18M | 219.54M | 185.88M | 104.17M |
| CurrentLiabilities | 96.30M | 91.34M | 49.34M | 18.63M |
| CurrentDeferredLiabilities | 788.00K | 44.00K | 75.00K | 113.00K |
| CurrentDeferredRevenue | 788.00K | 44.00K | 75.00K | 113.00K |
| CurrentDebtAndCapitalLeaseObligation | 887.00K | 497.00K | 806.00K | 723.00K |
| CurrentCapitalLeaseObligation | 887.00K | 497.00K | 806.00K | 723.00K |
| PayablesAndAccruedExpenses | 94.63M | 90.80M | 48.46M | 17.80M |
| CurrentAccruedExpenses | 59.27M | 52.04M | 27.04M | 11.36M |
| InterestPayable | 6.50M | 2.54M | 1.98M | 1.25M |
| Payables | 35.35M | 38.76M | 21.42M | 6.44M |
| AccountsPayable | 35.35M | 38.76M | 21.42M | 6.44M |
| TotalAssets | 399.48M | 388.97M | 312.16M | 157.38M |
| TotalNonCurrentAssets | 187.73M | 199.32M | 172.68M | 39.12M |
| NonCurrentDeferredAssets | 0.00 | 1.95M | 0.00 | |
| InvestmentsAndAdvances | 0.00 | 11.13M | ||
| LongTermEquityInvestment | 0.00 | 11.13M | ||
| InvestmentsinSubsidiariesatCost | 0.00 | 11.13M | ||
| GoodwillAndOtherIntangibleAssets | 176.69M | 187.03M | 162.38M | 26.17M |
| OtherIntangibleAssets | 176.36M | 186.70M | 162.04M | 25.84M |
| Goodwill | 332.00K | 332.00K | 332.00K | 332.00K |
| NetPPE | 11.04M | 12.29M | 10.31M | 11.00M |
| AccumulatedDepreciation | -12.22M | -11.01M | -10.07M | -9.06M |
| GrossPPE | 23.27M | 23.30M | 20.38M | 20.06M |
| Leases | 7.43M | 7.29M | 6.77M | 6.45M |
| OtherProperties | 13.71M | 13.86M | 11.35M | 11.77M |
| MachineryFurnitureEquipment | 2.13M | 2.15M | 2.26M | 1.84M |
| BuildingsAndImprovements | 6.79M | 7.51M | 5.93M | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 211.75M | 189.65M | 139.48M | 118.26M |
| OtherCurrentAssets | 2.13M | 3.41M | 1.75M | 118.00K |
| CurrentDeferredAssets | 0.00 | 409.00K | 0.00 | |
| PrepaidAssets | 12.28M | 11.69M | 7.20M | 3.35M |
| Inventory | 13.52M | 10.70M | 10.87M | 6.54M |
| FinishedGoods | 5.53M | 4.48M | 5.34M | 2.80M |
| WorkInProcess | 1.04M | 858.00K | 54.00K | 38.00K |
| RawMaterials | 6.96M | 5.36M | 5.48M | 3.71M |
| Receivables | 110.89M | 116.60M | 36.49M | 6.39M |
| DuefromRelatedPartiesCurrent | 0.00 | 228.00K | 228.00K | 139.00K |
| AccountsReceivable | 110.89M | 116.37M | 36.26M | 6.25M |
| AllowanceForDoubtfulAccountsReceivable | -27.03M | -20.15M | -15.25M | -779.00K |
| GrossAccountsReceivable | 137.92M | 136.52M | 51.51M | 7.03M |
| CashCashEquivalentsAndShortTermInvestments | 72.93M | 47.25M | 82.77M | 101.86M |
| OtherShortTermInvestments | 0.00 | 8.68M | 5.59M | 8.50M |
| CashAndCashEquivalents | 72.93M | 47.25M | 74.08M | 96.27M |
| CashFinancial | 72.93M | 47.25M | 74.08M | 96.27M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 42.76M | -60.88M | -148.71M | -6.07M |
| RepurchaseOfCapitalStock | 0.00 | -11.00M | ||
| RepaymentOfDebt | -230.90M | 0.00 | -59.75M | -18.00K |
| IssuanceOfDebt | 244.38M | 29.78M | 60.84M | 31.74M |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 138.07M | 22.66M |
| CapitalExpenditure | -1.10M | -38.67M | -152.55M | -7.77M |
| InterestPaidSupplementalData | 18.72M | 20.59M | 18.89M | 6.48M |
| IncomeTaxPaidSupplementalData | 93.00K | 374.00K | 0.00 | 75.00K |
| EndCashPosition | 72.93M | 47.25M | 74.08M | 96.27M |
| BeginningCashPosition | 47.25M | 74.08M | 96.27M | 42.17M |
| ChangesInCash | 25.68M | -26.84M | -22.18M | 54.10M |
| FinancingCashFlow | -12.72M | 28.53M | 126.53M | 54.14M |
| CashFlowFromContinuingFinancingActivities | -12.72M | 28.53M | 126.53M | 54.14M |
| NetOtherFinancingCharges | -26.66M | -2.36M | -13.01M | -876.00K |
| ProceedsFromStockOptionExercised | 467.00K | 1.11M | 379.00K | 642.00K |
| CashDividendsPaid | 0.00 | -127.00K | ||
| PreferredStockDividendPaid | 0.00 | -127.00K | ||
| NetPreferredStockIssuance | 0.00 | -345.00K | ||
| PreferredStockPayments | 0.00 | -11.00M | ||
| PreferredStockIssuance | 0.00 | 10.65M | ||
| NetCommonStockIssuance | 0.00 | 0.00 | 138.07M | 22.66M |
| CommonStockIssuance | 0.00 | 0.00 | 138.07M | 22.66M |
| NetIssuancePaymentsOfDebt | 13.47M | 29.78M | 1.09M | 31.72M |
| NetLongTermDebtIssuance | 13.47M | 29.78M | 1.09M | 31.72M |
| LongTermDebtPayments | -230.90M | 0.00 | -59.75M | -18.00K |
| LongTermDebtIssuance | 244.38M | 29.78M | 60.84M | 31.74M |
| InvestingCashFlow | -5.46M | -33.16M | -152.55M | -1.74M |
| CashFlowFromContinuingInvestingActivities | -5.46M | -33.16M | -152.55M | -1.74M |
| NetOtherInvestingChanges | 6.00M | |||
| NetInvestmentPurchaseAndSale | 0.00 | 5.51M | 0.00 | 0.00 |
| SaleOfInvestment | 0.00 | 5.51M | 0.00 | 0.00 |
| NetBusinessPurchaseAndSale | -4.36M | 0.00 | 0.00 | 9.83M |
| SaleOfBusiness | 9.83M | |||
| PurchaseOfBusiness | -4.36M | 0.00 | 0.00 | |
| NetIntangiblesPurchaseAndSale | -215.00K | -37.08M | -151.09M | -5.18M |
| PurchaseOfIntangibles | -215.00K | -37.08M | -151.09M | -5.18M |
| NetPPEPurchaseAndSale | -887.00K | -1.59M | -1.46M | -2.57M |
| SaleOfPPE | 0.00 | 30.00K | 0.00 | |
| PurchaseOfPPE | -887.00K | -1.59M | -1.46M | -2.60M |
| CapitalExpenditureReported | 0.00 | -12.59M | ||
| OperatingCashFlow | 43.86M | -22.20M | 3.84M | 1.71M |
| CashFlowFromContinuingOperatingActivities | 43.86M | -22.20M | 3.84M | 1.71M |
| ChangeInWorkingCapital | 185.00K | -44.63M | -7.13M | -5.57M |
| ChangeInOtherWorkingCapital | 744.00K | -31.00K | -38.00K | 97.00K |
| ChangeInPayablesAndAccruedExpense | -3.67M | 41.54M | 33.22M | 1.87M |
| ChangeInAccruedExpense | 936.00K | 4.05M | 1.43M | 936.00K |
| ChangeInPayable | -4.61M | 37.50M | 31.80M | 933.00K |
| ChangeInAccountPayable | -4.61M | 37.50M | 31.80M | 933.00K |
| ChangeInPrepaidAssets | 924.00K | -6.07M | -5.65M | -3.35M |
| ChangeInInventory | -2.82M | 165.00K | -4.33M | -2.32M |
| ChangeInReceivables | 5.01M | -80.23M | -30.34M | -1.86M |
| ChangesInAccountReceivables | 5.01M | -80.23M | -30.34M | -1.86M |
| OtherNonCashItems | 4.05M | 4.21M | 4.10M | 782.00K |
| StockBasedCompensation | 12.50M | 17.62M | 15.70M | 7.97M |
| ProvisionandWriteOffofAssets | 468.00K | 120.00K | 332.00K | 81.00K |
| AssetImpairmentCharge | 0.00 | 253.00K | 380.00K | 0.00 |
| DepreciationAmortizationDepletion | 19.68M | 14.54M | 12.34M | 3.67M |
| DepreciationAndAmortization | 19.68M | 14.54M | 12.34M | 3.67M |
| AmortizationCashFlow | 17.59M | 12.36M | 10.56M | 1.58M |
| AmortizationOfIntangibles | 17.59M | 12.36M | 10.56M | 1.58M |
| Depreciation | 2.09M | 2.17M | 1.78M | 2.09M |
| OperatingGainsLosses | 12.12M | 3.17M | 2.54M | 8.86M |
| EarningsLossesFromEquityInvestments | 0.00 | 3.17M | -3.09M | 14.05M |
| GainLossOnSaleOfPPE | 13.00K | 0.00 | 168.00K | -5.19M |
| GainLossOnSaleOfBusiness | 4.36M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | -5.14M | -17.48M | -24.41M | -14.09M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for HROW
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|